Visualization 1: 3D printed hollow core terahertz Bragg waveguides with defect layers for surface sensing applications

Rotation setup Originally published in Optics Express on 20 February 2017 (oe-25-4-4126

Immunohistochemical staining for MAL2 and TPD52 in non-cancerous mucosa and primary carcinoma tissues of patients with CRC.

<p>(A,B) Expression levels of MAL2 and TPD52 in non-cancerous mucosa and primary carcinoma tissues from patients with CRC were detected by immunohistochemical staining (×100, 100 μm; ×400, 20 μm). MAL2 and TPD52 expression levels were quantified as shown as the right bar charts. **P<0.01 compared with non-cancerous mucosa.</p

Expression comparison for MAL2 and TPD52 in tissues of patient with CRC.

<p>Expression comparison for MAL2 and TPD52 in tissues of patient with CRC.</p

TPD52 regulates migration and invasion in CRC SW480 cells.

<p>(A) SW480 cells were transfected with PG307-TPD52 overexpression vector (TPD52) or empty PG307 vector as negative control (Ctrl). Also, SW480 cells were transfected with siRNA for TPD52 (siTPD52) or control siRNA (siCtrl). Western blot analysis was used to detect TPD52 protein expression in cells using TPD52 antibody. GAPDH was detected as internal reference. (B,C) The cellular migration and invasion abilities were evaluated by Transwell assay. (D) Akt (Ser473) phosphorylation was detected by Western blotting using the corresponding antibody and Akt protein was examined. (E,F) TPD52-overexpressed SW480 cells were treated with 2 μM LY294002, the PI3K specific inhibitor, for 24 h, and migration and invasion abilities of TPD52-overexpressed and control cells were evaluated. *P<0.05, **P<0.01 compared with control cells; N.S., no significance.</p

Kaplan-Meier survival analysis in patients with CRC.

<p>(A) Overall survival curves for patients according to the negative (n = 49) and positive (n = 74) expression levels of MAL2 of immunohistochemical variables in tumor cells. (B) Overall survival curves for patients according to the negative (n = 37) and positive (n = 86) expression levels of TPD25 of immunohistochemical variables in tumor cells. (C) Overall survival curves for patients according to the positive and negative expression of MAL2 and TPD52 of immunohistochemical variables in tumor cells.</p